Gain Therapeutics (NASDAQ: GANX) shares Q3 2025 results and business update

Rhea-AI Filing Summary

Gain Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results for the third quarter ended September 30, 2025, along with a business update. The press release, dated November 12, 2025, is included as Exhibit 99.1. The company states that this information is being furnished under the rules governing current reports and is not considered filed for liability purposes or automatically incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001819411false00018194112025-11-122025-11-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 12, 2025

Gain Therapeutics, Inc.

(Exact Name of the Registrant as Specified in Charter)

Delaware		001-40237		85-1726310
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

​

4800 Montgomery Lane, Suite 220

Bethesda, Maryland 20814

(Address of principal executive offices) (Zip Code)

(301) 500-1556

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of exchange on which registered
Common Stock, $0.0001 par value	GANX	The NASDAQ Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

Item 2.02 Results of Operations and Financial Condition.

On November 12, 2025, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025, and a business update. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information and exhibit be deemed incorporated by reference into any of the Company’s filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The exhibits listed below are furnished as part of this Current Report on Form 8-K.

	​
Exhibit No.		Description
99.1	​	Gain Therapeutics, Inc. Press Release dated November 12, 2025
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL document).

​

​

​

​

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GAIN THERAPEUTICS, INC.
Date: November 12, 2025	By:	/s/ Gene Mack
	Name:		Gene Mack
	Title:		Chief Executive Officer ​

​

​

​

FAQ

What did Gain Therapeutics (GANX) disclose in this 8-K filing?

Gain Therapeutics disclosed that it issued a press release announcing its financial results for the third quarter ended September 30, 2025, and provided a business update, which is furnished as Exhibit 99.1.

Which period do the newly announced Gain Therapeutics (GANX) results cover?

The results announced by Gain Therapeutics cover the third quarter ended September 30, 2025.

How did Gain Therapeutics (GANX) provide its Q3 2025 financial results?

Gain Therapeutics provided its Q3 2025 financial results and business update through a press release dated November 12, 2025, furnished as Exhibit 99.1 to the current report.

Is the Gain Therapeutics (GANX) Q3 2025 press release considered filed with the SEC?

The company states that the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other filings unless expressly stated.

Who signed the Gain Therapeutics (GANX) current report related to Q3 2025 results?

The current report was signed on behalf of Gain Therapeutics, Inc. by Gene Mack, Chief Executive Officer.

What exhibits are included with this Gain Therapeutics (GANX) 8-K?

The 8-K includes Exhibit 99.1, the Gain Therapeutics press release dated November 12, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.